A detailed history of Swiss National Bank transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 126,500 shares of CRNX stock, worth $5.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
126,500
Previous 104,200 21.4%
Holding current value
$5.67 Million
Previous $3.71 Million 59.72%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$34.76 - $46.81 $775,148 - $1.04 Million
22,300 Added 21.4%
126,500 $5.92 Million
Q4 2023

Feb 06, 2024

SELL
$25.62 - $37.07 $312,564 - $452,254
-12,200 Reduced 10.48%
104,200 $3.71 Million
Q3 2023

Nov 08, 2023

BUY
$15.97 - $30.59 $546,174 - $1.05 Million
34,200 Added 41.61%
116,400 $3.46 Million
Q2 2023

Aug 09, 2023

BUY
$15.73 - $23.6 $14,157 - $21,240
900 Added 1.11%
82,200 $1.48 Million
Q1 2023

May 10, 2023

SELL
$15.31 - $21.1 $145,445 - $200,450
-9,500 Reduced 10.46%
81,300 $1.31 Million
Q4 2022

Feb 08, 2023

BUY
$15.49 - $19.05 $43,372 - $53,340
2,800 Added 3.18%
90,800 $1.66 Million
Q2 2022

Aug 09, 2022

BUY
$16.49 - $27.64 $153,357 - $257,052
9,300 Added 11.82%
88,000 $1.64 Million
Q1 2022

May 09, 2022

BUY
$17.15 - $28.31 $132,055 - $217,987
7,700 Added 10.85%
78,700 $1.73 Million
Q4 2021

Feb 08, 2022

BUY
$19.35 - $28.41 $414,090 - $607,974
21,400 Added 43.15%
71,000 $2.02 Million
Q2 2021

Aug 06, 2021

BUY
$15.9 - $21.15 $190,800 - $253,799
12,000 Added 31.91%
49,600 $935,000
Q1 2021

May 07, 2021

BUY
$13.3 - $17.55 $18,620 - $24,570
1,400 Added 3.87%
37,600 $575,000
Q2 2020

Aug 05, 2020

BUY
$13.04 - $23.23 $226,895 - $404,202
17,400 Added 92.55%
36,200 $634,000
Q1 2020

May 08, 2020

BUY
$11.52 - $26.46 $10,368 - $23,814
900 Added 5.03%
18,800 $276,000
Q2 2019

Aug 02, 2019

BUY
$21.48 - $27.71 $384,492 - $496,009
17,900 New
17,900 $448,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.41B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.